PDGFRB and neoplasm: Zhou et al., 2021 found that the RTKs, including VEGFR and PDGFR, are overexpressed in LSCC tissue and a multi-targeted protein kinase inhibitor, anlotinib, can effectively achieve the anti-tumor effect on LUSC (Zhou et al., 2021).